Item 1.01. Entry into a Material Definitive Agreement.
On June 15, 2023, MedTech Acquisition Corporation, a Delaware corporation
("MedTech" or the "Company"), issued a promissory note (the "Extension Note") in
the aggregate principal amount of up to $137,375.28 to the Company's sponsor,
MedTech Acquisition Sponsor LLC (the "Sponsor") pursuant to which the Sponsor
agreed to loan to the Company up to $137,375.28 to deposit into the Company's
trust account (the "Trust Account") for the shares of Class A common stock of
the Company (the "Public Shares") that were not redeemed in connection with the
extension of the Company's termination date from June 22, 2023 to September 22,
2023 or such earlier date as determined by the board of directors of the Company
(the "Board"). The Extension Note bears no interest and is repayable in full
upon the date of the consummation of an initial business combination (the
"Business Combination").
The Company will deposit $0.04 per share into the Trust Account for each month
(commencing on June 23, 2023 and ending on the 22ndday of each subsequent
month), or portion thereof, that is needed by the Company to complete a Business
Combination until September 22, 2023 or such earlier date as determined by the
Board (the "Extension").
The issuance of the Extension Note was made pursuant to the exemption from
registration contained in Section 4(a)(2) of the Securities Act of 1933, as
amended.
The foregoing description of the Extension Note does not purport to be complete
and is qualified in its entirety by reference to the full text of the Extension
Note, a copy of which is filed with this Current Report on Form 8-K as Exhibit
10.1, and is incorporated herein by reference.
Item 2.03. Creation of a Direct Financial Obligation or an Obligation Under an
Off-balance Sheet Arrangement of a Registrant.
The disclosure contained in Item 1.01 of this Current Report on Form 8-K is
incorporated by reference in this Item 2.03.
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal
Year.
On June 12, 2023, the Company held a special meeting of stockholders (the
"Meeting"). At the Meeting, the Company's stockholders approved (1) an amendment
to the Company's Amended and Restated Certificate of Incorporation, including
the amendment thereto (the "Charter"), to extend the date by which the Company
must consummate its Business Combination from June 22, 2023 to September 22,
2023 (or such earlier date as determined by the Board); (2) an amendment to the
Charter such that subject to the rights of the holders of any outstanding class
of preferred stock, the number of authorized shares of any class of common stock
or preferred stock may be increased or decreased (but not below the number of
shares thereof then outstanding) by the affirmative vote of the holders of a
majority of the outstanding shares of the Company's capital stock entitled to
vote thereon, irrespective of the provisions of Section 242(b)(2) of the
Delaware General Corporation Law; (3) an amendment to the Charter to provide for
the right of the holder of the Company's Class B common stock, par value $0.0001
per share (the "Founder Shares"), to convert into Class A common stock, par
value $0.0001 per share, on a one-for-one basis at any time prior to the closing
of a Business Combination at the option of the holder of Founder Shares; and (4)
amendments to the Charter to eliminate from the Charter the limitation that the
Company may not redeem public shares to the extent that such redemption would
result in the Company having net tangible assets of less than $5,000,001 (all
the aforementioned amendments, collectively, the "Charter Amendments"). The
Company filed the Charter Amendments with the Secretary of State of the State of
Delaware on June 12, 2023.
The foregoing description of the Charter Amendments does not purport to be
complete and is qualified in its entirety by reference to the Charter
Amendments, a copy of which is attached as Exhibit 3.1 hereto and is
incorporated by reference herein.
Item 5.07 Submission of Matters to a Vote of Security Holders
At the Meeting, an aggregate of 7,497,322 shares of the Company's common stock,
which represents a quorum of the outstanding shares of common stock entitled to
vote as of the record date of April 28, 2023, were represented in person or by
proxy at the Meeting.
At the Meeting, the Company's stockholders voted on the following proposals,
each of which was approved:
(1) The Extension Amendment Proposal - a proposal to amend the Company's amended
and restated certificate of incorporation to extend the date by which the
Company has to consummate a Business Combination from June 22, 2023 to September
22, 2023 (or such earlier date as determined by the Board). The following is a
tabulation of the votes with respect to this proposal, which was approved by the
Company's stockholders:
FOR AGAINST ABSTAIN
6,333,932 1,163,390 0
(2) Section 242(b)(2) Amendment Proposal - a proposal to amend the Company's
amended and restated certificate of incorporation such that subject to the
rights of the holders of any outstanding class of preferred stock, the number of
authorized shares of any class of common stock or preferred stock may be
increased or decreased (but not below the number of shares thereof then
outstanding) by the affirmative vote of the holders of a majority of the
outstanding shares of the Company's capital stock entitled to vote thereon,
irrespective of the provisions of Section 242(b)(2) of the Delaware General
Corporation Law. The following is a tabulation of the votes with respect to this
proposal, which was approved by the Company's stockholders:
FOR AGAINST ABSTAIN
common stock 7,496,754 568 0
Class A common stock 1,246,754 568 0
Class B common stock 6,250,000 0 0
(3) Founder Share Amendment Proposal - a proposal to amend the Company's amended
and restated certificate of incorporation to provide for the right of the holder
of the Founder Shares to convert into Class A common stock, par value $0.0001
per share, on a one-for-one basis at any time prior to the closing of a Business
Combination at the option of the holder of the Founder Shares. The following is
a tabulation of the votes with respect to this proposal, which was approved by
the Company's stockholders:
FOR AGAINST ABSTAIN
7,496,750 572 0
(4) Redemption Limitation Amendment Proposal - a proposal to amend the Company's
amended and restated certificate of incorporation to eliminate the limitation
that the Company may not redeem public shares to the extent that such redemption
would result in the Company having net tangible assets of less than $5,000,001
in order to allow the Company to redeem public shares irrespective of whether
such redemption would exceed the redemption limitation. The following is a
tabulation of the votes with respect to this proposal, which was approved by the
Company's stockholders:
FOR AGAINST ABSTAIN
7,496,690 322 310
In connection with the Meeting, stockholders holding 808,628 Public Shares
exercised their right to redeem their shares for a pro rata portion of the funds
in the Trust Account. As a result, approximately $8.48 million (approximately
$10.49 per Public Share) will be removed from the Trust Account to pay such
holders and approximately $12.00 million will remain in the Trust Account.
Following redemptions, the Company has 1,144,794 public shares outstanding, and
the Company will deposit $45,791.76 into the Trust Account of which 50% will be
drawn down under the Extension Note and 50% will be funded by TriSalus Life
Sciences, Inc., a Delaware corporation, pursuant to the Agreement and Plan of
Merger entered into on November 11, 2022.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following exhibits are filed with this Form 8-K:
Exhibit No. Description of Exhibits
3.1 Second Amendment to Amended and Restated Certificate of
Incorporation.
10.1 Promissory Note issued to MedTech Acquisition Sponsor LLC, dated
June 15, 2023.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
© Edgar Online, source Glimpses